Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor α chain, epithelial-to-mesenchymal transition

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1561-1569

  Khawam, Krystel ^a   Giron Michel, Julien ^a   Gu, Yanhong ^a,e   Perier, Aurélie ^a   Giuliani, Massimo ^a   Caignard, Anne ^a   Devocelle, Aurore ^a   Ferrini, Silvano ^c   Fabbi, Marina ^c   Charpentier, Bernard ^a   Ludwig, Andreas ^d   Chouaib, Salem ^b   Azzarone, Bruno ^a,f   Eid, Pierre ^a  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF GENOA   (Italy)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e NANJING MEDICAL UNIVERSITY   (China)

^f HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CANCER; KIDNEY TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; CARCINOMA, SMALL CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MEMBRANE; EPITHELIAL CELLS; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MESODERM; NEOPLASM METASTASIS; RECEPTORS, INTERLEUKIN-15; SODIUM ACETATE; TETRADECANOYLPHORBOL ACETATE; TUMOR CELLS, CULTURED;

EID: 60549116915     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3198     Document Type: Article

References (53)

1. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006;6:595-601.
2. Teague RM, Sather BD, Sacks JA, et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006;12:335-41.
3. Kobayashi H, Dubois S, Sato N, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 2005;105:721-7.
4. Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, Yoshikai Y. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer 2002;99:573-8.
5. Seike M, Yanaihara N, Bowman ED, et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst 2007;99:1257-69.
6. Allen C, Duffy S, Teknos T, et al. Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 2007;13:3182-90.
7. Barzegar C, Meazza R, Pereno R, et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene 1998;16:2503-12.
8. Budagian V, Bulanova E, Orinska Z, et al. Reverse signaling through membrane-bound interleukin-15. J Biol Chem 2004;279:42192-201.
9. Kuniyasu H, Ohmori H, Sasaki T, et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 2003;9:4802-10.
10. Nguyen ST, Hasegawa S, Tsuda H, et al. Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma. Cancer Sci 2007;98:740-6.
11. Pereno R, Giron-Michel J, Gaggero A, et al. IL-15/IL-15Rα intracellular trafficking in human melanoma cells and signal transduction through the IL-15Rα. Oncogene 2000;19:5153-62.
12. Sasahira T, Sasaki T, Kuniyasu H. Interleukin-15 and transforming growth factor α are associated with depletion of tumor-associated macrophages in colon cancer. J Exp Clin Cancer Res 2005;24:69-74.
13. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006;17:259-80.
14. Budagian V, Bulanova E, Orinska Z, et al. Natural soluble interleukin-15Rα is generated by cleavage that involves the tumor necrosis factor-α-converting enzyme (TACE/ADAM17). J Biol Chem 2004;279:40368-75.
15. Bulanova E, Budagian V, Duitman E, et al. Soluble Interleukin IL-15Rα is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15. J Biol Chem 2007;282:13167-79.
16. Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor α-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004;173:1681-8.
17. Giron-Michel J, Giuliani M, Fogli M, et al. Membrane-bound and soluble IL-15/IL-15Rα complexes display differential signaling and functions on human hematopoietic progenitors. Blood 2005;106:2302-10.
18. Mortier E, Quemener A, Vusio P, et al. Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ. Hyperagonist IL-15 × IL-15R α fusion proteins. J Biol Chem 2006;281:1612-9.
19. Bulfone-Paus S, Bulanova E, Budagian V, Paus R. The interleukin-15/ interleukin-15 receptor system as a model for juxtacrine and reverse signaling. BioEssays 2006;28:362-77.
20. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Rα recycles and presents IL-15 In trans to neighboring cells. Immunity 2002;17:537-47.
21. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996;62:543-5.
22. Shinozaki M, Hirahashi J, Lebedeva T, et al. IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest 2002;109:951-60.
23. Trinder P, Seitzer U, Gerdes J, Seliger B, Maeurer M. Constitutive and IFN-γ regulated expression of IL-7 and IL-15 in human renal cell cancer. Int J Oncol 1999;14:23-31.
24. Wittnebel S, Da Rocha S, Giron-Michel J, et al. Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis. Cancer Res 2007;67:5594-9.
25. Viey E, Fromont G, Escudier B, et al. Phosphostim-activated γ δ T cells kill autologous metastatic renal cell carcinoma. J Immunol 2005;174:1338-47.
26. Hundhausen C, Misztela D, Berkhout TA, et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003;102:1186-95.
27. Giron-Michel J, Fogli M, Gaggero A, et al. Detection of a functional hybrid receptor γc/GM-CSFRβ in human hematopoietic CD34+ cells. J Exp Med 2003;197:763-75.
28. Giuliani M, Giron-Michel J, Negrini S, et al. Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS ONE 2008;3:e2241.
29. Gaggero A, Azzarone B, Andrei C, et al. Differential intracellular trafficking, secretion and endosomal localization of two IL-15 isoforms. Eur J Immunol 1999;29:1265-74.
30. Vecchi M, Rudolph-Owen LA, Brown CL, Dempsey PJ, Carpenter G. Tyrosine phosphorylation and proteolysis. Pervanadate-induced, metalloprotease-dependent cleavage of the ErbB-4 receptor and amphiregulin. J Biol Chem 1998;273:20589-95.
31. Kaplan DR. Delivery of interleukin 2 for immunotherapy. J Chromatogr B Biomed Appl 1994;662:315-23.
32. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004;85:47-64.
33. Schober M, Raghavan S, Nikolova M, et al. Focal adhesion kinase modulates tension signaling to control actin and focal adhesion dynamics. J Cell Biol 2007;176:667-80.
34. Cheng TJ, Lai YK. Identification of mitogen-activated protein kinase-activated protein kinase-2 as a vimentin kinase activated by okadaic acid in 9L rat brain tumor cells. J Cell Biochem 1998;71:169-81.
35. Vepachedu R, Gorska MM, Singhania N, Cosgrove GP, Brown KK, Alam R. Unc119 regulates myofibroblast differentiation through the activation of Fyn and the p38 MAPK pathway. J Immunol 2007;179:682-90.
36. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-18.
37. Hugo H, Ackland ML, Blick T, et al. Epithelialmesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-83.
38. Olsen SK, Ota N, Kishishita S, et al. Crystal structure of the interleukin-15 receptor α complex: insights into trans and cis presentation. J Biol Chem 2007;282:37191-204.
39. Gore-Hyer E, Shegogue D, Markiewicz M, et al. TGF-β and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 2002;283:F707-16.
40. Nightingale J, Patel S, Suzuki N, et al. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J Am Soc Nephrol 2004;15:21-32.
41. Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res 2006;312:387-400.
42. Hong T, Grabel LB. Migration of F9 parietal endoderm cells is regulated by the ERK pathway. J Cell Biochem 2006;97:1339-49.
43. Webb DJ, Donais K, Whitmore LA, et al. FAK-Src signaling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004;6:154-61.
44. Badoual C, Bouchaud G, Agueznay Nel H, et al. The soluble a chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res 2008;68:3907-14.
45. Zhang M, Tang J, Li X. Interleukin-1β-induced transdifferentiation of renal proximal tubular cells is mediated by activation of JNK and p38 MAPK. Nephron Exp Nephrol 2005;99:e68-76.
46. Li M, Hering-Smith KS, Simon EE, Batuman V. Myeloma light chains induce epithelial-mesenchymal transition in human renal proximal tubule epithelial cells. Nephrol Dial Transplant 2008;23:860-70.
47. Wang Y, Zhang J, Yi XJ, Yu FS. Activation of ERK1/2 MAP kinase pathway induces tight junction disruption in human corneal epithelial cells. Exp Eye Res 2004;78:125-36.
48. Burns WC, Kantharidis P, Thomas MC. The role of tubular epithelial-mesenchymal transition in progressive kidney disease. Cells Tissues Organs 2007;185:222-31.
49. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15:1-12.
50. Wahab NA, Mason RM. A critical look at growth factors and epithelial-to-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 2006;104:e129-34.
51. Ge N, Nishioka Y, Nakamura Y, et al. Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int Arch Allergy Immunol 2004;135:235-42.
52. Rathmell WK, Chen S. VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Rev Anticancer Ther 2008;8:63-73.
53. Seliger B, Schlaf G. Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol 2007;17:444-50.